These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11915728)

  • 21. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.
    Zhang Y; Ma B; Zhou Y; Zhang M; Qiu X; Sui Y; Zhang X; Ma B; Fan Q
    Breast Cancer Res Treat; 2007 Nov; 105(3):277-86. PubMed ID: 17187233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of lymphokine-activated cytotoxic T lymphocytes stimulated by dendritic cells and autologous tumor from a patient with gastric cancer and their effects in vitro.
    Yoshikawa T; Yanoma S; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
    Hepatogastroenterology; 2005; 52(61):289-92. PubMed ID: 15783052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
    G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
    Kim HS; Choo YS; Koo T; Bang S; Oh TY; Wen J; Song SY
    Immunol Lett; 2006 Mar; 103(2):142-8. PubMed ID: 16313973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients.
    Beatty P; Hanisch FG; Stolz DB; Finn OJ; Ciborowski P
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):781s-787s. PubMed ID: 11300473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen].
    Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ
    Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of specific cytolytic T lymphocytes using fusions of hepatocellular carcinoma (HCC) patient-derived dendritic cells and allogeneic HCC cell line.
    Yin XY; Wang L; Lu MD; Li BJ; Huang JF
    Hepatogastroenterology; 2008; 55(81):155-9. PubMed ID: 18507097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y; Itoh T; Nukaya I; Kawashima I; Okugawa K; Yano Y; Yamamoto Y; Naitoh K; Shimizu K; Imura K; Fuji N; Fujiwara H; Ochiai T; Itoi H; Sonoyama T; Hagiwara A; Takesako K; Yamagishi H
    Int J Oncol; 2004 Apr; 24(4):909-17. PubMed ID: 15010829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
    Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
    J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
    Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
    Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.